| GTO ID | GTC1672 |
| Trial ID |
NCT02963311
|
| Disease |
Familial Hypercholesterolemia
|
| Altered gene | PCSK9 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | ALN-PCSSC|Inclisiran|KJX839|Leqvio |
| Co-treatment | Standard of Care |
| Location approved | EU, UK, Australia, Canada, Israel, US, Saudi Arabia, Japan, China |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia (HoFH) |
| Year | 2016 |
| Country | Netherlands|South Africa|United States |
| Company sponsor | The Medicines Company |
| Other ID(s) | MDCO-PCS-16-02 |